BioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
The Pharma Letter2d
BioNTech revenues beat forecasts despite declining
Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...
BioNTech (NasdaqGS:BNTX) Faces Sales Decline To €2,751 Million In 2024 And Projects Lower 2025 Revenue
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
Nasdaq3d
BioNTech SE Q4 Income Retreats, But Beats Estimates
(RTTNews) - BioNTech SE (BNTX) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's earnings totaled $259.5 million ...
BioNTech price target lowered to $151 from $172 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.
BioNTech Stock Drops as Sales Outlook Disappoints
BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.